Ovarian Cancer Drugs Market to 2027 - Global Analysis and Forecasts By Drug Class (Alkylating Agents, Mitotic Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR Inhibitors, PARP Inhibitors, Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography
Report Code: TIPRE00003750 No. of Pages: 159 Category: Pharmaceuticals Status: Upcoming
MARKET INTRODUCTION
Ovarian cancer is one of the most common type of cancer in women that mainly affects the women who have been through menopause. The common symptoms of ovarian cancer includes bloating, pelvic or abdominal pain, fatigue, upset stomach, back pain and others. The prime cause of ovarian cancer is unknown however, women are at high risk of getting it being over 50 years of age and have a family history for the disease.
MARKET DYNAMICS
The ovarian cancer drugs market is anticipated to grow in the forecast, owing to the factors such as increasing incidence of ovarian cancer, advancements in cancer therapies and others. In addition, several initiatives undertaken by various government and non-government organizations for research and investment into ovarian cancer drugs therapeutics is expected to offer significant growth opportunities in the market during the forecast period.
MARKET SCOPE
The "Global Ovarian Cancer Drugs Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of ovarian cancer drugs market with detailed market segmentation by product, application, end user and geography. The global ovarian cancer drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading ovarian cancer drugs market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global ovarian cancer drugs market is segmented on the basis of drug class, distribution channel and geography. Based on drug class, the market is segmented as alkylating agents, mitotic inhibitors, antirheumatics, antipsoriatics, VEGF/VEGFR inhibitors, PARP inhibitors and others. On the basis of distribution channel, the global ovarian cancer drugs market is segmented into, hospital pharmacies, retail pharmacies and online pharmacies.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global ovarian cancer drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The ovarian cancer drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting ovarian cancer drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the ovarian cancer drugs market in these regions.
MARKET PLAYERS
The reports cover key developments in the ovarian cancer drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from ovarian cancer drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for ovarian cancer drugs market in the global market. Below mentioned is the list of few companies engaged in the ovarian cancer drugs market.
The report also includes the profiles of key ovarian cancer drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
Ovarian cancer is one of the most common type of cancer in women that mainly affects the women who have been through menopause. The common symptoms of ovarian cancer includes bloating, pelvic or abdominal pain, fatigue, upset stomach, back pain and others. The prime cause of ovarian cancer is unknown however, women are at high risk of getting it being over 50 years of age and have a family history for the disease.
MARKET DYNAMICS
The ovarian cancer drugs market is anticipated to grow in the forecast, owing to the factors such as increasing incidence of ovarian cancer, advancements in cancer therapies and others. In addition, several initiatives undertaken by various government and non-government organizations for research and investment into ovarian cancer drugs therapeutics is expected to offer significant growth opportunities in the market during the forecast period.
MARKET SCOPE
The "Global Ovarian Cancer Drugs Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of ovarian cancer drugs market with detailed market segmentation by product, application, end user and geography. The global ovarian cancer drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading ovarian cancer drugs market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global ovarian cancer drugs market is segmented on the basis of drug class, distribution channel and geography. Based on drug class, the market is segmented as alkylating agents, mitotic inhibitors, antirheumatics, antipsoriatics, VEGF/VEGFR inhibitors, PARP inhibitors and others. On the basis of distribution channel, the global ovarian cancer drugs market is segmented into, hospital pharmacies, retail pharmacies and online pharmacies.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global ovarian cancer drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The ovarian cancer drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting ovarian cancer drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the ovarian cancer drugs market in these regions.
The reports cover key developments in the ovarian cancer drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from ovarian cancer drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for ovarian cancer drugs market in the global market. Below mentioned is the list of few companies engaged in the ovarian cancer drugs market.
The report also includes the profiles of key ovarian cancer drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- ALLERGAN
- AstraZeneca
- F.Hoffmann La Roche, Ltd.
- Pfizer, Inc.
- Merck KGaA
- Syndax
- CLOVIS ONCOLOGY
- Boehringer Ingelheim International GmbH
- TESARO, Inc.
- Amgen Inc.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Ovarian Cancer Drugs Market - By Drug Class
1.3.2 Ovarian Cancer Drugs Market - By Distribution Channel
1.3.3 Ovarian Cancer Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. OVARIAN CANCER DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. OVARIAN CANCER DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. OVARIAN CANCER DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. OVARIAN CANCER DRUGS - GLOBAL MARKET OVERVIEW
6.2. OVARIAN CANCER DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. OVARIAN CANCER DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. ALKYLATING AGENTS
7.3.1. Overview
7.3.2. Alkylating Agents Market Forecast and Analysis
7.4. MITOTIC INHIBITORS
7.4.1. Overview
7.4.2. Mitotic Inhibitors Market Forecast and Analysis
7.5. ANTIRHEUMATICS
7.5.1. Overview
7.5.2. Antirheumatics Market Forecast and Analysis
7.6. ANTIPSORIATICS
7.6.1. Overview
7.6.2. Antipsoriatics Market Forecast and Analysis
7.7. VEGF/VEGFR INHIBITORS
7.7.1. Overview
7.7.2. VEGF/VEGFR Inhibitors Market Forecast and Analysis
7.8. PARP INHIBITORS
7.8.1. Overview
7.8.2. PARP Inhibitors Market Forecast and Analysis
7.9. OTHERS
7.9.1. Overview
7.9.2. Others Market Forecast and Analysis
8. OVARIAN CANCER DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACIES
8.3.1. Overview
8.3.2. Hospital Pharmacies Market Forecast and Analysis
8.4. RETAIL PHARMACIES
8.4.1. Overview
8.4.2. Retail Pharmacies Market Forecast and Analysis
8.5. ONLINE PHARMACIES
8.5.1. Overview
8.5.2. Online Pharmacies Market Forecast and Analysis
9. OVARIAN CANCER DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Ovarian Cancer Drugs Market Overview
9.1.2 North America Ovarian Cancer Drugs Market Forecasts and Analysis
9.1.3 North America Ovarian Cancer Drugs Market Forecasts and Analysis - By Drug Class
9.1.4 North America Ovarian Cancer Drugs Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Ovarian Cancer Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 Canada Ovarian Cancer Drugs Market
9.1.5.1.1 Canada Ovarian Cancer Drugs Market by Drug Class
9.1.5.1.2 Canada Ovarian Cancer Drugs Market by Distribution Channel
9.1.5.2 Mexico Ovarian Cancer Drugs Market
9.1.5.2.1 Mexico Ovarian Cancer Drugs Market by Drug Class
9.1.5.2.2 Mexico Ovarian Cancer Drugs Market by Distribution Channel
9.1.5.3 US Ovarian Cancer Drugs Market
9.1.5.3.1 US Ovarian Cancer Drugs Market by Drug Class
9.1.5.3.2 US Ovarian Cancer Drugs Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe Ovarian Cancer Drugs Market Overview
9.2.2 Europe Ovarian Cancer Drugs Market Forecasts and Analysis
9.2.3 Europe Ovarian Cancer Drugs Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Ovarian Cancer Drugs Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Ovarian Cancer Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Ovarian Cancer Drugs Market
9.2.5.1.1 Germany Ovarian Cancer Drugs Market by Drug Class
9.2.5.1.2 Germany Ovarian Cancer Drugs Market by Distribution Channel
9.2.5.2 France Ovarian Cancer Drugs Market
9.2.5.2.1 France Ovarian Cancer Drugs Market by Drug Class
9.2.5.2.2 France Ovarian Cancer Drugs Market by Distribution Channel
9.2.5.3 Italy Ovarian Cancer Drugs Market
9.2.5.3.1 Italy Ovarian Cancer Drugs Market by Drug Class
9.2.5.3.2 Italy Ovarian Cancer Drugs Market by Distribution Channel
9.2.5.4 Spain Ovarian Cancer Drugs Market
9.2.5.4.1 Spain Ovarian Cancer Drugs Market by Drug Class
9.2.5.4.2 Spain Ovarian Cancer Drugs Market by Distribution Channel
9.2.5.5 United Kingdom Ovarian Cancer Drugs Market
9.2.5.5.1 United Kingdom Ovarian Cancer Drugs Market by Drug Class
9.2.5.5.2 United Kingdom Ovarian Cancer Drugs Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Ovarian Cancer Drugs Market Overview
9.3.2 Asia-Pacific Ovarian Cancer Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Ovarian Cancer Drugs Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Ovarian Cancer Drugs Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Ovarian Cancer Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Ovarian Cancer Drugs Market
9.3.5.1.1 Australia Ovarian Cancer Drugs Market by Drug Class
9.3.5.1.2 Australia Ovarian Cancer Drugs Market by Distribution Channel
9.3.5.2 China Ovarian Cancer Drugs Market
9.3.5.2.1 China Ovarian Cancer Drugs Market by Drug Class
9.3.5.2.2 China Ovarian Cancer Drugs Market by Distribution Channel
9.3.5.3 India Ovarian Cancer Drugs Market
9.3.5.3.1 India Ovarian Cancer Drugs Market by Drug Class
9.3.5.3.2 India Ovarian Cancer Drugs Market by Distribution Channel
9.3.5.4 Japan Ovarian Cancer Drugs Market
9.3.5.4.1 Japan Ovarian Cancer Drugs Market by Drug Class
9.3.5.4.2 Japan Ovarian Cancer Drugs Market by Distribution Channel
9.3.5.5 South Korea Ovarian Cancer Drugs Market
9.3.5.5.1 South Korea Ovarian Cancer Drugs Market by Drug Class
9.3.5.5.2 South Korea Ovarian Cancer Drugs Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Ovarian Cancer Drugs Market Overview
9.4.2 Middle East and Africa Ovarian Cancer Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Ovarian Cancer Drugs Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Ovarian Cancer Drugs Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Ovarian Cancer Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Ovarian Cancer Drugs Market
9.4.5.1.1 South Africa Ovarian Cancer Drugs Market by Drug Class
9.4.5.1.2 South Africa Ovarian Cancer Drugs Market by Distribution Channel
9.4.5.2 Saudi Arabia Ovarian Cancer Drugs Market
9.4.5.2.1 Saudi Arabia Ovarian Cancer Drugs Market by Drug Class
9.4.5.2.2 Saudi Arabia Ovarian Cancer Drugs Market by Distribution Channel
9.4.5.3 U.A.E Ovarian Cancer Drugs Market
9.4.5.3.1 U.A.E Ovarian Cancer Drugs Market by Drug Class
9.4.5.3.2 U.A.E Ovarian Cancer Drugs Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Ovarian Cancer Drugs Market Overview
9.5.2 South and Central America Ovarian Cancer Drugs Market Forecasts and Analysis
9.5.3 South and Central America Ovarian Cancer Drugs Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Ovarian Cancer Drugs Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Ovarian Cancer Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Ovarian Cancer Drugs Market
9.5.5.1.1 Brazil Ovarian Cancer Drugs Market by Drug Class
9.5.5.1.2 Brazil Ovarian Cancer Drugs Market by Distribution Channel
9.5.5.2 Argentina Ovarian Cancer Drugs Market
9.5.5.2.1 Argentina Ovarian Cancer Drugs Market by Drug Class
9.5.5.2.2 Argentina Ovarian Cancer Drugs Market by Distribution Channel
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. OVARIAN CANCER DRUGS MARKET, KEY COMPANY PROFILES
11.1. ALLERGAN
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. ASTRAZENECA
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. F.HOFFMANN LA ROCHE, LTD.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. PFIZER, INC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. MERCK KGAA
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. SYNDAX
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. CLOVIS ONCOLOGY
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. TESARO, INC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. AMGEN INC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Ovarian Cancer Drugs Market - By Drug Class
1.3.2 Ovarian Cancer Drugs Market - By Distribution Channel
1.3.3 Ovarian Cancer Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. OVARIAN CANCER DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. OVARIAN CANCER DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. OVARIAN CANCER DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. OVARIAN CANCER DRUGS - GLOBAL MARKET OVERVIEW
6.2. OVARIAN CANCER DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. OVARIAN CANCER DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. ALKYLATING AGENTS
7.3.1. Overview
7.3.2. Alkylating Agents Market Forecast and Analysis
7.4. MITOTIC INHIBITORS
7.4.1. Overview
7.4.2. Mitotic Inhibitors Market Forecast and Analysis
7.5. ANTIRHEUMATICS
7.5.1. Overview
7.5.2. Antirheumatics Market Forecast and Analysis
7.6. ANTIPSORIATICS
7.6.1. Overview
7.6.2. Antipsoriatics Market Forecast and Analysis
7.7. VEGF/VEGFR INHIBITORS
7.7.1. Overview
7.7.2. VEGF/VEGFR Inhibitors Market Forecast and Analysis
7.8. PARP INHIBITORS
7.8.1. Overview
7.8.2. PARP Inhibitors Market Forecast and Analysis
7.9. OTHERS
7.9.1. Overview
7.9.2. Others Market Forecast and Analysis
8. OVARIAN CANCER DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACIES
8.3.1. Overview
8.3.2. Hospital Pharmacies Market Forecast and Analysis
8.4. RETAIL PHARMACIES
8.4.1. Overview
8.4.2. Retail Pharmacies Market Forecast and Analysis
8.5. ONLINE PHARMACIES
8.5.1. Overview
8.5.2. Online Pharmacies Market Forecast and Analysis
9. OVARIAN CANCER DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Ovarian Cancer Drugs Market Overview
9.1.2 North America Ovarian Cancer Drugs Market Forecasts and Analysis
9.1.3 North America Ovarian Cancer Drugs Market Forecasts and Analysis - By Drug Class
9.1.4 North America Ovarian Cancer Drugs Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Ovarian Cancer Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 Canada Ovarian Cancer Drugs Market
9.1.5.1.1 Canada Ovarian Cancer Drugs Market by Drug Class
9.1.5.1.2 Canada Ovarian Cancer Drugs Market by Distribution Channel
9.1.5.2 Mexico Ovarian Cancer Drugs Market
9.1.5.2.1 Mexico Ovarian Cancer Drugs Market by Drug Class
9.1.5.2.2 Mexico Ovarian Cancer Drugs Market by Distribution Channel
9.1.5.3 US Ovarian Cancer Drugs Market
9.1.5.3.1 US Ovarian Cancer Drugs Market by Drug Class
9.1.5.3.2 US Ovarian Cancer Drugs Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe Ovarian Cancer Drugs Market Overview
9.2.2 Europe Ovarian Cancer Drugs Market Forecasts and Analysis
9.2.3 Europe Ovarian Cancer Drugs Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Ovarian Cancer Drugs Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Ovarian Cancer Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Ovarian Cancer Drugs Market
9.2.5.1.1 Germany Ovarian Cancer Drugs Market by Drug Class
9.2.5.1.2 Germany Ovarian Cancer Drugs Market by Distribution Channel
9.2.5.2 France Ovarian Cancer Drugs Market
9.2.5.2.1 France Ovarian Cancer Drugs Market by Drug Class
9.2.5.2.2 France Ovarian Cancer Drugs Market by Distribution Channel
9.2.5.3 Italy Ovarian Cancer Drugs Market
9.2.5.3.1 Italy Ovarian Cancer Drugs Market by Drug Class
9.2.5.3.2 Italy Ovarian Cancer Drugs Market by Distribution Channel
9.2.5.4 Spain Ovarian Cancer Drugs Market
9.2.5.4.1 Spain Ovarian Cancer Drugs Market by Drug Class
9.2.5.4.2 Spain Ovarian Cancer Drugs Market by Distribution Channel
9.2.5.5 United Kingdom Ovarian Cancer Drugs Market
9.2.5.5.1 United Kingdom Ovarian Cancer Drugs Market by Drug Class
9.2.5.5.2 United Kingdom Ovarian Cancer Drugs Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Ovarian Cancer Drugs Market Overview
9.3.2 Asia-Pacific Ovarian Cancer Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Ovarian Cancer Drugs Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Ovarian Cancer Drugs Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Ovarian Cancer Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Ovarian Cancer Drugs Market
9.3.5.1.1 Australia Ovarian Cancer Drugs Market by Drug Class
9.3.5.1.2 Australia Ovarian Cancer Drugs Market by Distribution Channel
9.3.5.2 China Ovarian Cancer Drugs Market
9.3.5.2.1 China Ovarian Cancer Drugs Market by Drug Class
9.3.5.2.2 China Ovarian Cancer Drugs Market by Distribution Channel
9.3.5.3 India Ovarian Cancer Drugs Market
9.3.5.3.1 India Ovarian Cancer Drugs Market by Drug Class
9.3.5.3.2 India Ovarian Cancer Drugs Market by Distribution Channel
9.3.5.4 Japan Ovarian Cancer Drugs Market
9.3.5.4.1 Japan Ovarian Cancer Drugs Market by Drug Class
9.3.5.4.2 Japan Ovarian Cancer Drugs Market by Distribution Channel
9.3.5.5 South Korea Ovarian Cancer Drugs Market
9.3.5.5.1 South Korea Ovarian Cancer Drugs Market by Drug Class
9.3.5.5.2 South Korea Ovarian Cancer Drugs Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Ovarian Cancer Drugs Market Overview
9.4.2 Middle East and Africa Ovarian Cancer Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Ovarian Cancer Drugs Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Ovarian Cancer Drugs Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Ovarian Cancer Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Ovarian Cancer Drugs Market
9.4.5.1.1 South Africa Ovarian Cancer Drugs Market by Drug Class
9.4.5.1.2 South Africa Ovarian Cancer Drugs Market by Distribution Channel
9.4.5.2 Saudi Arabia Ovarian Cancer Drugs Market
9.4.5.2.1 Saudi Arabia Ovarian Cancer Drugs Market by Drug Class
9.4.5.2.2 Saudi Arabia Ovarian Cancer Drugs Market by Distribution Channel
9.4.5.3 U.A.E Ovarian Cancer Drugs Market
9.4.5.3.1 U.A.E Ovarian Cancer Drugs Market by Drug Class
9.4.5.3.2 U.A.E Ovarian Cancer Drugs Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Ovarian Cancer Drugs Market Overview
9.5.2 South and Central America Ovarian Cancer Drugs Market Forecasts and Analysis
9.5.3 South and Central America Ovarian Cancer Drugs Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Ovarian Cancer Drugs Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Ovarian Cancer Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Ovarian Cancer Drugs Market
9.5.5.1.1 Brazil Ovarian Cancer Drugs Market by Drug Class
9.5.5.1.2 Brazil Ovarian Cancer Drugs Market by Distribution Channel
9.5.5.2 Argentina Ovarian Cancer Drugs Market
9.5.5.2.1 Argentina Ovarian Cancer Drugs Market by Drug Class
9.5.5.2.2 Argentina Ovarian Cancer Drugs Market by Distribution Channel
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. OVARIAN CANCER DRUGS MARKET, KEY COMPANY PROFILES
11.1. ALLERGAN
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. ASTRAZENECA
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. F.HOFFMANN LA ROCHE, LTD.
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. PFIZER, INC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. MERCK KGAA
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. SYNDAX
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. CLOVIS ONCOLOGY
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. TESARO, INC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. AMGEN INC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies
1. ALLERGAN
2. AstraZeneca
3. F.Hoffmann La Roche, Ltd.
4. Pfizer, Inc.
5. Merck KGaA
6. Syndax
7. CLOVIS ONCOLOGY
8. Boehringer Ingelheim International GmbH
9. TESARO, Inc.
10. Amgen Inc.
1. ALLERGAN
2. AstraZeneca
3. F.Hoffmann La Roche, Ltd.
4. Pfizer, Inc.
5. Merck KGaA
6. Syndax
7. CLOVIS ONCOLOGY
8. Boehringer Ingelheim International GmbH
9. TESARO, Inc.
10. Amgen Inc.